Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| 1 |
Apple
AAPL
|
+$460M |
| 2 |
GE Aerospace
GE
|
+$402M |
| 3 |
CELG
Celgene Corp
CELG
|
+$381M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$379M |
| 5 |
Johnson & Johnson
JNJ
|
+$358M |
Top Sells
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$243M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| 1 | Healthcare | 17.59% |
| 2 | Technology | 14.12% |
| 3 | Financials | 10.92% |
| 4 | Consumer Discretionary | 9.85% |
| 5 | Real Estate | 7.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2076
HCI Group
HCI
$2.34B
| $3.25M | ﹤0.01% |
80,219
-33,900
| -30% | -$1.37M |
|
2077
Silvercrest Asset Management
SAMG
$137M
| $3.23M | ﹤0.01% |
230,424
+13,068
| +6% | +$183K |
|
2078
Elanco Animal Health
ELAN
$9.2B
| $3.22M | ﹤0.01% |
+95,200
| New | +$3.22M |
|
2079
Sunoco
SUN
$6.87B
| $3.21M | ﹤0.01% |
102,700
-37,700
| -27% | -$1.18M |
|
2080
Collegium Pharmaceutical
COLL
$1.13B
| $3.21M | ﹤0.01% |
+244,100
| New | +$3.21M |
|
2081
Puma Biotechnology
PBYI
$229M
| $3.21M | ﹤0.01% |
252,200
+160,300
| +174% | +$2.04M |
|
2082
FB Financial Corp
FBK
$2.83B
| $3.2M | ﹤0.01% |
87,500
+11,900
| +16% | +$436K |
|
2083
DallasNews
DALN
$84.7M
| $3.2M | ﹤0.01% |
216,918
+5,665
| +3% | +$83.6K |
|
2084
Stantec
STN
$12.6B
| $3.2M | ﹤0.01% |
133,500
+18,600
| +16% | +$446K |
|
2085
Distribution Solutions Group
DSGR
$1.45B
| $3.2M | ﹤0.01% |
174,200
+66,422
| +62% | +$1.22M |
|
|
VIA
2086
DELISTED
Via Renewables, Inc. Class A Common Stock
VIA
| $3.19M | ﹤0.01% |
57,062
+40,162
| +238% | +$2.25M |
|
2087
AmeriServ Financial
ASRV
$47.1M
| $3.18M | ﹤0.01% |
766,391
-1,976
| -0.3% | -$8.2K |
|
|
QUMU
2088
DELISTED
Qumu Corp.
QUMU
| $3.18M | ﹤0.01% |
765,371
+84,190
| +12% | +$349K |
|
|
BNFT
2089
DELISTED
Benefitfocus, Inc.
BNFT
| $3.18M | ﹤0.01% |
116,945
-18,894
| -14% | -$513K |
|
2090
Parker-Hannifin
PH
$96.7B
| $3.17M | ﹤0.01% |
+18,650
| New | +$3.17M |
|
|
SAFE
2091
Safehold
SAFE
$1.18B
| $3.17M | ﹤0.01% |
+52,408
| New | +$3.17M |
|
2092
Amicus Therapeutics
FOLD
$2.4B
| $3.17M | ﹤0.01% |
+253,800
| New | +$3.17M |
|
|
EIGR
2093
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $3.17M | ﹤0.01% |
9,954
+656
| +7% | +$209K |
|
|
CBLK
2094
DELISTED
Carbon Black, Inc. Common Stock
CBLK
| $3.16M | ﹤0.01% |
+189,200
| New | +$3.16M |
|
|
NBRV
2095
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $3.16M | ﹤0.01% |
5,197
+1,774
| +52% | +$1.08M |
|
|
CWBC
2096
Community West Bancshares
CWBC
$405M
| $3.13M | ﹤0.01% |
145,592
+26,211
| +22% | +$563K |
|
|
CBM
2097
DELISTED
Cambrex Corporation
CBM
| $3.12M | ﹤0.01% |
66,700
-57,700
| -46% | -$2.7M |
|
2098
Southwest Gas
SWX
$5.68B
| $3.12M | ﹤0.01% |
34,800
+30,584
| +725% | +$2.74M |
|
2099
AMES National
ATLO
$183M
| $3.12M | ﹤0.01% |
115,021
+6,421
| +6% | +$174K |
|
2100
Corvus Pharmaceuticals
CRVS
$429M
| $3.12M | ﹤0.01% |
833,098
+51,398
| +7% | +$192K |
|